Figure 3From: Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trialsChange from baseline in HbA1c at week 18 (A)*and week 24 (B)†(FAS LOCF). *Data based on all six clinical trials. †Data based on four clinical trials.Back to article page